CRBU Stock Analysis: Buy, Sell, or Hold?
CRBU - Caribou Biosciences, Inc. Common Stock
$2.07
-0.07 (-3.27%)
▼
5d:
+1.97%
30d:
-5.91%
90d:
+33.55%
BUY
HIGH Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 12, 2026
0d
Smart Money Accumulation
CRBU is down 7.2% this week, but smart money is accumulating calls. Top strike: $2.5 2026-07-17 with 1,194 OI. Call ratio: 100% View Scanner →
Strength: 8.6/10
Get Alerted When CRBU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
3 traders called CRBU this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: CRBU shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: CRBU shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: CRBU is currently trading at $2.07, which is considered fair relative to its 30-day fair value range of $1.93 to $2.20.
Technical Outlook: Technically, CRBU is in a strong uptrend. Immediate support is located at $1.84, while resistance sits at $2.32. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: CRBU has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $12.00 (+460.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CRBU is in a strong uptrend. Immediate support is located at $1.84, while resistance sits at $2.32. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: CRBU has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $12.00 (+460.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.93 -
$2.20
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
81.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.3%)
- BULLISH: Trading 460.7% below Wall St target ($12.00)
Trading Range Analysis
30-Day Trading Range
$1.93 -
$2.20
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.85
Resistance Level
$2.32
Current Trend
Strong Uptrend
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.52
Wall Street Target
$12.00
(+460.7%)
Revenue Growth (YoY)
1.9%
Share & Embed Analysis
Last updated: May 18, 2026 1:03 PM ET
Data refreshes hourly during market hours. Next update: 2:03 PM
Data refreshes hourly during market hours. Next update: 2:03 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRBU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Barbara G Mcclung
SELL
6938 shares
2026-02-24
Ruhi Ahmad Khan
SELL
6938 shares
2026-02-24
Timothy P Kelly
SELL
3147 shares
2026-02-24
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 55 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 55 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$203 | 52 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$32 | 62 BUY |
